Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients
Artikel i vetenskaplig tidskrift, 2014

Prevalence of neurocognitive impairment in HIV-1 infected patients is reported to be high. Whether this is a result of active HIV-related neurodegeneration is unclear. We examined axonal injury in HIV-1 patients by measuring the light subunit of neurofilament protein (NFL) in CSF with a novel, sensitive method.With a cross-sectional design, CSF concentrations of neurofilament protein light (NFL) (marker of neuronal injury), neopterin (intrathecal immunoactivation) and CSF/Plasma albumin ratio (blood-brain barrier integrity) were analyzed on CSF from 252 HIV-infected patients, subdivided into untreated neuroasymptomatics (n = 200), HIV-associated dementia (HAD) (n = 14) and on combinations antiretroviral treatment (cART) (n = 85), and healthy controls (n = 204). 46 HIV-infected patients were included in both treated and untreated groups, but sampled at different timepoints. Furthermore, 78 neuroasymptomatic patients were analyzed before and after treatment initiation. While HAD patients had the highest NFL concentrations, elevated CSF NFL was also found in 33% of untreated neuroasymptomatic patients, mainly in those with blood CD4+ cell counts below 250 cells/μL. CSF NFL concentrations in the untreated neuroasymptomatics and treated groups were equivalent to controls 18.5 and 3.9 years older, respectively. Neopterin correlated with NFL levels in untreated groups while the albumin ratio correlated with NFL in both untreated and treated groups. Increased CSF NFL indicates ongoing axonal injury in many neuroasymptomatic patients. Treatment decreases NFL, but treated patients retain higher levels than controls, indicating either continued virus-related injury or an aging-like effect of HIV infection. NFL correlates with neopterin and albumin ratio, suggesting an association between axonal injury, neuroinflammation and blood-brain barrier permeability. NFL appears to be a sensitive biomarker of subclinical and clinical brain injury in HIV and warrants further assessment for broader clinical use.

Neuropsychological testing

HIV

HIV infections

Albumins

brain damage

blood counts

Cerebrospinal fluid

Central nervous system

Författare

Jan Jessen Krut

Göteborgs universitet

Tomas Mellberg

Göteborgs universitet

R.W. Price

University of California

Lars Hagberg

Göteborgs universitet

D. Fuchs

Medizinische Universitat Innsbruck

Lars Rosengren

Göteborgs universitet

Staffan Nilsson

Chalmers, Matematiska vetenskaper, matematisk statistik

Göteborgs universitet

Henrik Zetterberg

Göteborgs universitet

Magnus Gisslén

Göteborgs universitet

PLoS ONE

1932-6203 (ISSN)

Vol. 9 2 Art. no. e88591- e88591

Ämneskategorier

Klinisk medicin

Neurovetenskaper

DOI

10.1371/journal.pone.0088591

Mer information

Senast uppdaterat

2018-02-28